GeoVax to Present at HIV/AIDS Vaccine Symposium at New York Academy of Sciences on May 19

GeoVax to Present at HIV/AIDS Vaccine Symposium at New York Academy of Sciences on May 19
Chief Scientific Officer Harriet L. Robinson to Speak on the Ongoing Development and Testing of Company's HIV/AIDS Vaccines


SMYRNA, Ga., May 17 -- GeoVax Labs, Inc. (OTC Bulletin Board GOVXD.), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will speak at a symposium devoted to the development of HIV/AIDS vaccines to be held at the New York Academy of Sciences in New York City on Wednesday, May 19.


The one-day symposium, titled "HIV/AIDS: Vaccines and alternate strategies for treatment and prevention," will cover a range of issues facing researchers working toward the development of an HIV/AIDS vaccine, presenting challenges as well as solutions.  These challenges include:  developing HIV vaccines to prevent or control infection, genetic diversity of the virus, and nonhuman primate models of infection.  The symposium will also cover mechanisms that can be used to reduce HIV transmission now and in conjunction with a future vaccine.


The symposium is being presented by the Global HIV Vaccine Enterprise, and the Vaccine Science Discussion Group at the New York Academy of Sciences.  The Academy, a membership organization with over 24,000 members in 140 countries, was founded in 1817.  Its members include research scientists at universities and industry, as well as representatives of business, government, and policy organizations.  Its Board of Governors and President's Council include 26 Nobel laureates and other prominent leaders of academia and industry, based in New York and around the world.


Robert T. McNally, GeoVax's president and CEO, commented:  "Dr. Robinson is spearheading our Company's research efforts to develop and test viable preventative and therapeutic AIDS vaccines.  We are pleased that she will be presenting the highly encouraging results of our vaccine trials at this prestigious event,  and in so doing will shine a spotlight on our achievements to date and the potential successes to come."


About GeoVax Labs, Inc.


GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. The company is focused on developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.  Preventative Phase 1 human clinical trials testing various combinations and doses of the GeoVax  DNA and MVA vaccines have demonstrated outstanding safety as well as excellent ability to raise anti-HIV immune responses. Based on the successful results from  Phase 1 testing, the U.S. sponsored HIV Vaccine Trials Network  has initiated  Phase 2 testing. GeoVax's Phase 2a human trial began in January 2009 and will involve 225 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals already infected with HIV. Long term,  GeoVax plans to  grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.


Forward-Looking Statements


Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.


Contact

 

At The Investor Relations Group:
Investor Relations
James Carbonara / Jason Strominger

or

Public Relations
Janet Vasquez / Robin O'Malley
(212) 825-3210

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.